ANALYSIS OF THE RESULTS OF NEODJUVANT TREATMENT IN PATIENTS WITH CONSIDERATION FOR THE IMMUNOPHENOTYPICAL FEATURES OF BREAST CANCER
https://doi.org/10.17650/1994-4098-2008-0-4-31-34
Abstract
The efficiency of neoadjuvant chemotherapy is directly related to the expression of CD95 (FAS/APO-1) apoptosis receptor on cancer cells, which is confirmed with the pathomorphism and changes of CD95-positive cells during neoadjuvant chemotherapy (the most effective CAF regimen is cyclophosphan, doxorubicin, and 5- fluorouracil).
About the Authors
A. A. Subbotina
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy
of Medical Sciences, Moscow; Department of Oncology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
V. P. Letyagin
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy
of Medical Sciences, Moscow; Department of Oncology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
N. N. Tupitsyn
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy
of Medical Sciences, Moscow; Department of Oncology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
I. V. Vysotskaya
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy
of Medical Sciences, Moscow; Department of Oncology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
V. D. Yermilova
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy
of Medical Sciences, Moscow; Department of Oncology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
References
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2005 г. Вестн РОНЦ им. Н.Н. Блохина 2007;18(2):прил. 1.
2. Parkin D., Pisani P., Ferley J. Global cancer statistics. CA Cancer J Clin 1999;49:33—64.
3. Артамонова Е.В. Роль иммунофенотипирования опухолевых клеток в диагностике и прогнозе рака молочной железы. Автореф. дис. ... докт. мед. наук. М., 2003.
4. Барышников А.Ю., Тоневицкий А.Г. Моноклональные антитела в лаборатории и клинике. М., 1997. с. 99—105.
5. Абашин С.Ю. Неоадъювантная системная терапия в комплексном лечении местно-распространенного рака молочной железы. Совр онкол 2000;2(4):133.
6. Алимходжаева Л.Т. Иммуноморфологические изменения в опухолях молочной железы при неоадъювантной химиотерапии в условиях искусственной гипергликемии. Опух жен репрод сист 2008;(2):35—7.
7. Кушлинский Н.Е., Портной С.М., Лактионов К.П. Рак молочной железы. М., 2005. с. 174—94.
8. Тупицын Н.Н., Васильев М.Б., Огнерубов Н.А. Клиническое значение экспрессии трансферринового рецептора на клетках рака молочной железы. В кн.: Новое в онкологии. Под ред. И.В. Под- дубной, Н.А. Огнерубова. Воронеж, 2001. с. 197—209.
9. Singh G., Singh D.P., Gupta D., Muralikrishna B.V. Neoadjuvant chemotherapy in locally advanced breast cancer. J Surg Oncol 1996;61(1):38—41.
10. Bernard D.J., Courjal F., Maurizis J.C. et al. Effect of epidermal growth factor in HLA class I and class II transcription and protein expression in human breast adenocarcinoma cell lines. Br J Cancer 1992;66(1):88—92.
Review
For citations:
Subbotina A.A., Letyagin V.P., Tupitsyn N.N., Vysotskaya I.V., Yermilova V.D. ANALYSIS OF THE RESULTS OF NEODJUVANT TREATMENT IN PATIENTS WITH CONSIDERATION FOR THE IMMUNOPHENOTYPICAL FEATURES OF BREAST CANCER. Tumors of female reproductive system. 2008;(4):31-34. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-4-31-34
Views:
511
Email this article 